Patents by Inventor John Wityak

John Wityak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isoxazoline and isoxazole fibrogen receptor antagonists
    Patent number: 6114328
    Abstract: This invention relates to novel isoxazolines and isoxazoles which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex or the vitronectin receptor, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.
    Type: Grant
    Filed: November 25, 1997
    Date of Patent: September 5, 2000
    Assignee: Dupont Pharmaceuticals Company
    Inventors: John Wityak, Chu-Biao Xue, Thais Motria Sielecki-Dzurdz, Richard Eric Olson, William Frank Degrado, Gary Avonn Cain, Douglas Guy Batt, Donald Pinto, Munir Alwan Hussain, Shaker Ahmed Mousa
  • Isoxazoline, isothiazoline and pyrazoline factor Xa inhibitors
    Patent number: 5939418
    Abstract: Isoxazolines, isothiazolines and pyrazolines which are inhibitors of Factor Xa, pharmaceutical compositions containing these compounds, and methods of using these compounds as anticoagulant agents for treatment and prevention of thromboembolic disorders. The compounds can be represented by the formula: ##STR1## where X is O, S or NR.sup.15.
    Type: Grant
    Filed: December 17, 1996
    Date of Patent: August 17, 1999
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Mimi Lifen Quan, John Wityak, Robert Anthony Galemmo, Jr., Petrus F. W. Stouten, James Russell Pruitt, Donald J. P. Pinto
  • Isoxazoline and isoxazole fibrinogen receptor antagonists
    Patent number: 5849736
    Abstract: This invention relates to novel isoxazolines and isoxazoles which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex or the vitronectin receptor, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: December 15, 1998
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: John Wityak, Chu-Biao Xue, Thais Motria Sielecki-Dzurdz, Richard Eric Olson, William Frank Degrado, Gary Avonn Cain, Douglas Guy Batt, Donald Pinto, Munir Alwan Hussain, Shaker Ahmed Mousa
  • Cyclic compounds linked by a heterocyclic ring useful as inhibitors of platelet glycoprotein IIb/IIIa
    Patent number: 5849693
    Abstract: This invention relates to novel cyclic compounds linked by a heterocyclic ring system, which are useful as antagonists of the platelet glycoprotein IIb/IIIa complex, to pharmaceutical compositions containing such cyclic compounds, and to methods of using these compounds for the inhibition of platelet aggregation.
    Type: Grant
    Filed: March 12, 1997
    Date of Patent: December 15, 1998
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Gregory James Wells, John Wityak, Anju Parthasarathy, William Frank DeGrado, Sharon Anne Jackson, Shaker Ahmed Mousa
  • Isoxazoline fibrinogen receptor antagonists
    Patent number: 5811441
    Abstract: This invention relates to improved isoxazoline compounds including, but not limited to N.sup.2 -(3,5-dimethylisoxazole-4-sulfonyl)-N.sup.3 -?3-(4-amidinophenyl)isoxazolin-5(R)-ylacetyl!-(S)-2,3-diaminopropionic acid, which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex, to pharmaceutical compositions containing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.
    Type: Grant
    Filed: September 3, 1997
    Date of Patent: September 22, 1998
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Richard Eric Olson, John Wityak
  • Cyclic compounds linked by a heterocyclic ring useful as inhibitors of platelet glycoprotein IIB/IIIA
    Patent number: 5773411
    Abstract: This invention relates to novel cyclic compounds linked by a heterocyclic ring system, which are useful as antagonists of the platelet glycoprotein IIb/IIIa complex, to pharmaceutical compositions containing such cyclic compounds, and to methods of using these compounds for the inhibition of platelet aggregation. A representative compound of the invention is cyclo-(D-Val-N(Me)Arg-Gly-Asp-?5-aminomethyl!-2-furoate).
    Type: Grant
    Filed: November 14, 1994
    Date of Patent: June 30, 1998
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Gregory James Wells, John Wityak, Anju Parthasarathy, William Frank DeGrado, Sharon Anne Jackson, Shaker Ahmed Mousa
  • Integrin receptor antagonists
    Patent number: 5710159
    Abstract: This invention relates to novel heterocycle compounds including but not limited to 3-?3-?3-(imidazolin-2-yl amino)propyloxy!isoxazol-5-ylcarbonylamino!-2-(benzyloxycarbonylamino)-pro pionic acid, which are useful as antagonists of the .alpha..sub.v .beta..sub.3 and related integrin receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion and the treatment of angiogenic disorders, inflammation, bone degradation, tumors, metastases, thrombosis, and other cell aggregation-related conditions.
    Type: Grant
    Filed: May 9, 1996
    Date of Patent: January 20, 1998
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Matthew Ernst Voss, Prabhakar Kondaji Jadhav, Joanne Marie Smallheer, Douglas Guy Batt, William John Pitts, John Wityak
  • Boronic acid and ester inhibitors of thrombin
    Patent number: 5698538
    Abstract: Novel boronic acid and ester and carboxyl-modified amino acid compounds of the Formula I, which are inhibitors of trypsin-like enzymes, are disclosed :R.sup.1 --Z--CHR.sup.2 --A,where R.sup.1, Z, R.sup.2 arid A are defined within.
    Type: Grant
    Filed: July 26, 1996
    Date of Patent: December 16, 1997
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Eugene Cruz Amparo, William Henry Miller, Gregory James Pacofsky, John Wityak, Patricia Carol Weber, John Jonas Vytautas Duncia, Joseph Basil Santella, III
  • Boronic acid and ester inhibitors of thrombin
    Patent number: 5563127
    Abstract: Novel boronic acid and ester and carboxyl-modified amino acid compounds of the Formula I, which are inhibitors of trypsin-like enzymes, are disclosed :R.sup.1 --Z--CHR.sup.2 --A,where R.sup.1, Z, R.sup.2 and A are defined within.
    Type: Grant
    Filed: December 27, 1994
    Date of Patent: October 8, 1996
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Eugene C. Amparo, William H. Miller, Gregory J. Pacofsky, John Wityak, Patricia C. Weber, John J. V. Duncia, Joseph B. Santella, III
  • Isoxazoline compounds useful as fibrinogen receptor antagonists
    Patent number: 5446056
    Abstract: This invention relates to novel isoxazolines which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.
    Type: Grant
    Filed: September 12, 1994
    Date of Patent: August 29, 1995
    Assignee: The Du Pont Merck Pharmaceutical Company
    Inventors: John Wityak, Thais M. Sielecki-Dzurdz